Epidemiology of eight common rheumatic diseases in China: A large-scale cross-sectional survey in Beijing

Department of Rheumatology and Immunology, Peking University People's Hospital, 11 Xizhimen South St, Beijing 100044, China.
Rheumatology (Oxford, England) (Impact Factor: 4.48). 12/2011; 51(4):721-9. DOI: 10.1093/rheumatology/ker370
Source: PubMed


To investigate the prevalence of eight common rheumatic diseases in a large Chinese population.
A population-based epidemiological investigation of the prevalence of eight common rheumatic diseases in a suburb of Beijing was conducted in 14 642 individuals. A community-based survey was carried out using a screening questionnaire. Positive responders were included in a clinical and laboratory examination. Diagnosis was based on the criteria of ACR or those used widely in literature.
A total of 10 556 inhabitants were interviewed. Forty-three cases of RA were identified with an age-adjusted prevalence of 0.28% (95% CI 0.19%, 0.41%). Gout was diagnosed with a crude prevalence of 0.09% (95% CI 0.05%, 0.17%). Psoriasis was reported in 28 individuals with a prevalence of 0.27% (95% CI 0.18%, 0.38%). This included two cases diagnosed with PsA, resulting in a prevalence of 7.14% (95% CI 0.88%, 23.5%) in psoriasis patients and 0.02% (95% CI 0%, 0.07%) in the general population. Three individuals were identified with SLE, with a prevalence of 0.03% (95% CI 0%, 0.06%). One individual was identified with SSc and the calculated prevalence was 0.01% (95% CI 0%, 0.05%). One case of Behçet's disease was identified, giving a prevalence of 0.01% (95% CI 0%, 0.05%).
This large-scale epidemiological survey provides an estimate of the burden of rheumatic diseases in China.

  • Source
    • "In recent years, epidemiological evidence has shown that the tuberculosis epidemic situation in China is not optimistic, and although the incidence has declined, the level remains high (3,4). In addition, there has been a marked increase in the prevalence of gout, which highly correlates with economic development as manifested by dietary and lifestyle changes (5,6). To the best of our knowledge, there have been no previous cases reported with regard to patients with NPC complicated with pulmonary tuberculosis and gout. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In China, the incidence of nasopharyngeal carcinoma (NPC) and tuberculosis remains high. Additionally, there has been a marked increase in the prevalence of gout. In recent years, there has been an increase in the number of coexisting diseases. To the best of our knowledge, there have been no previous cases reported in the literature with regard to patients suffering from NPC complicated with pulmonary tuberculosis and gout. The present study describes the case of a 59yearold male with this condition. The patient received a combination of antitumor, antituberculosis and antigout therapies, and experienced no severe adverse reactions during treatment. At present, the patient's Eastern Cooperative Oncology Group performance status is good, there has been no local recurrence or distant metastasis of the NPC, and the pulmonary tuberculosis and gout are well controlled. The aim of this study was to provide insight into the treatment of patients suffering from coexisting conditions.
    Full-text · Article · May 2014 · Oncology letters
  • Source
    • "Systemic lupus erythematosus, an autoimmune illness with a wide spectrum of manifestations, affects multiple organ systems and is associated with considerable morbidity and mortality. The incidence of SLE appears to be higher in China compared to America and Europe, and millions of Chinese patients are suffering from this disease [19]–[21]. Due to deeper understanding of the disease itself and its management, the disease is becoming chronic and controllable. However, because it is incurable and runs a variable course over the patient’s remaining years, SLE still profoundly affects health status, especially the HRQoL[22]–[24]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To adapt and assess the validity and reliability of LupusQoL for use in Chinese patients with systemic lupus erythematosus (SLE). Debriefing interviews of subjects with SLE guided the language modifications of the tool. The process of adaptation proceeded according to the guideline and pre-testing results of LupusQoL-China. 220 SLE patients completed LupusQoL-China and a generic preference-based measurement of health EuroQoL scale (EQ-5D), and 20 patients repeated them after 2 weeks. Internal consistency (ICR) and test-retest (TRT) reliability, convergent and discriminant validity were examined. Factor analysis and Rasch analysis were performed. The mean (SD) age of the 208 subjects with SLE was 33.93 (±9.19) years. ICR and TRT of the eight domains ranged from 0.811 to 0.965 and 0.836 to 0.974, respectively. The LupusQoL-China domains demonstrated substantial evidence of construct validity when compared with equivalent domains on the EQ-5D (physical health and usual activities r = -0.63, pain and pain/discomfort r = -0.778, emotional health and anxiety/depression r = -0.761, planning and usual activities r = -0.560). Most LupusQoL-China domains could discriminate patients with varied disease activities and end-organ damage (according to SELENA-SLEDAI and SLICC-DI). The principal component analysis revealed six factors, and confirmatory factor analysis result of which is similar to eight factors model. These results provide evidence that the LupusQoL-China is valid as a disease-specific HRQoL assessment tool for Chinese patients with SLE.
    Preview · Article · May 2013 · PLoS ONE
  • Source

    Preview · Article · Jul 2012 · Rheumatology (Oxford, England)
Show more